Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 4, 2006, Pages 458-464

  Huang, Hsu Shan ^a   Chiu, Hui Fen ^b   Tao, Chi Wei ^c   Chen, In Been ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

Author keywords

Adriamycin; Amidoanthraquinone; Cytotoxicity; Mitoxantrone; Structure activity relationship; XTT colorimetric assay

Indexed keywords

1,5 BIS(2 ETHYLAMINOETHYLAMIDO)ANTHRAQUINONE; 1,5 BIS(2 HEXYLAMINOPROPIONAMIDO)ANTHRAQUINONE; 1,5 BIS(2 ISOPROPYLAMINOPROPIONAMIDO)ANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; DOXORUBICIN; MITOXANTRONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORIMETRY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERCALATING AGENTS; MITOXANTRONE; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645550875     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.458     Document Type: Article

References (21)

1. Huang H. S., Chiu H. F., Chiou J. F., Yeh P. F., Tao C. W., Jeng W. R., Arch. Pharm. (Weinheim), 335, 481 (2002).
2. Huang H. S., Chiou J. F., Chiu H. F., Hwang J. M., Lin P. Y., Tao C. W., Yeh P. F., Jeng W. R., Chem. Pharm. Bull., 50, 1491-1494 (2002).
3. Huang H. S., Chiou J. F., Fong Y., Hou C. C., Lu Y. C., Wang J. Y., Shih J. W., Pan Y. R., Lin J. J., J. Med. Chem., 46, 3300 (2003).
4. Huang H. S., Chiu H. F., Yeh P. F., Yuan C. L., Helv. Chim. Acta, 87, 999 (2004).
5. Huang H. S., Chiu H. F., Lee A. L., Guo C. L., Yuan C. L., Bioorg. Med. Chem., 12, 6163 (2004).
6. Huang H. S., Chiu H. F., Lu W. C., Yuan C. L., Chem. Pharm. Bull., 53, 1136-1139 (2005).
7. Perry P. J., Reszka A. P., Wood A. A., Read M. A., Gowan S. M., Dosanjh H. S., Trent J. O., Jenkins T. C., Kelland. R., Neidle S., J. Med. Chem., 41, 4873 (1998).
8. Perry P. J., Gowan S. M., Reszka A. P., Polucci P., Jenkins T. C., Kelland L. R., Neidle S., J. Med. Chem., 41, 3253 (1998).
9. Buschini A., Poli P., Rossi C., Mutagenesis, 18, 25 (2003).
10. Arcamone F., Lloydia, 40, 45 (1977).
11. Henry D. W., "Cancer Chemotherapy," Chap. 2, ed. by Sartorelli A. C., American Chemical Society, Washington, DC, 1976.
12. Teich L., Daub K. S., Krugel V., Nissler L., Gebhardt R., Eger K., Bioorg. Med. Chem., 12, 5961 (2004).
13. Huang H. S., Hwang J. M., Jen Y. M., Lin J. J., Lee K. Y., Shi C. H., Hsu H. C., Chem. Pharm. Bull., 49, 969-973 (2001).
14. Huang H. S., Chou C. L., Guo C. L., Yuan C. L., Lu Y. C., Shieh F. Y., Lin J. J., Bioorg. Med. Chem., 13, 1435 (2005).
15. Sun D., Thompson B., Cathers B. E., Salazar M., Kerwin S. M., Trent J. O., Jenkins T. C., Neidle S., Hurley L. H., J. Med. Chem., 40, 2113 (1997).
16. Collier D. A., Neidle S., J. Med. Chem., 31, 847 (1988).
17. Agbandje M., Jenkins T. C., McKenna R., Reszka A. P., Neidle S., J. Med. Chem., 35, 1418 (1992).
18. Perry P. J., Read M. A., Davies R. T., Gowan S. M., Reszka A. P., Wood A. A., Kelland L. R., Neidle S., J. Med. Chem., 42, 2679 (1999).
19. Read M. A., Wood A. A., Harrison J. R., Gowan S. M., Kelland L. R., Dosanjh H. Neidle S., J. Med. Chem., 42, 4538 (1999).
20. Zagotto G., Moro S., Uriarte E., Ferrazzi E., Palu G., Palumbo M., Anticancer Drug Des., 12, 99 (1997).
21. Keppler M. D., Read M. A., Perry P. J., Trent J. O., Jenkins T. C., Reszka A. P., Neidle S., Fox K. R., Eur. J. Biochem., 263, 817 (1999).